CINP Max Hamilton Memorial Award 2008

Dr George Papakostas

George I. Papakostas is Assistant Professor of Psychiatry at Harvard Medical School and Director of Treatment-Resistant Depression Studies in the Department of Psychiatry at Massachusetts General Hospital in Boston, Massachusetts.  He is also a member of the Scientific Advisory Board of the Mallinckrodt General Clinical Research Center at Massachusetts General Hospital.  The focus of Dr Papakostas’ research includes the pharmacotherapy of major depressive disorder including treatment-resistant depression, the study of the “placebo” effect and it’s relevance to clinical trial design in major depressive disorder, and the study of clinical and biologic predictors, moderators, and mediators of treatment outcome in major depressive disorder.  Dr Papakostas has received numerous national and international research awards from sources including the American College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologium, the New Clinical Drug Evaluation Unit of the National Institute of Mental Health, the World Federation of Societies of Biological Psychiatry, the International College of Psychosomatic Medicine, and the American Foundation for Suicide Prevention.  He is an author or co-author of over 100 clinical and scientific publications and book chapters.  His publications have appeared in Biological Psychiatry, the Journal of Clinical Psychiatry, and the Journal of Clinical Psychopharmacology, among other journals.  He is also on the editorial board of the journal “Psychiatry Research”, and has served as a reviewer for more than 40 journals, including the Archives of General Psychiatry, Biological Psychiatry, and the Journal of Clinical Psychiatry.  Dr. Papakostas is often invited to lecture on a wide range topics pertaining to the treatment of depression throughout the United States and abroad.

Dr. Papakostas attended Medical School at the New York University School of Medicine. He completed his residency in adult Psychiatry at Massachusetts General Hospital and McLean Hospital, and a fellowship in Clinical Neuropsychopharmacology at Massachusetts General Hospital that was funded by the American College of Neuropsychopharmacology.